{
    "clinical_study": {
        "@rank": "114119", 
        "acronym": "STORM", 
        "arm_group": {
            "arm_group_label": "Rituximab, Temsirolimus, DHAP, intravenous", 
            "arm_group_type": "Experimental", 
            "description": "This is a multicenter, open label, single arm, phase II study. There will be no placebo usage within this trial. In the part I, dose escalation part, of this trial 6 patients will be included in each dose level. There will be 4 cohorts, administering up to a maximum of 4 cycles 25 mg, 50 mg, 75mg or 100mg Temsirolimus in combination with Rituximab and DHAP.\nTreatment regimen part I:\nPart I - Cohort A, B, C, D, X Temsirolimus 25 (A), 50 (B), 75 (C),100 (D) or 15 (X) mg, Day 1, 8, Rituximab (375 mg/m\u00b2 day 2) Dexamethasone 40mg day 3-6 Cisplatine 100 mg/m\u00b2 day 3 Cytarabine 2x2 g/m\u00b2 day 4\n...repeat day 22, up to a maximum of 4 cycles\nIn the part II of the trial 40 patients will be included to receive the full target dose, established within the part I of the study."
        }, 
        "brief_summary": {
            "textblock": "The STORM-trial consists of two parts. In the part I  (dose escalation of Temsirolimus) the\n      primary objective is to establish a maximum tolerated dose of Temsirolimus in combination\n      with Rituximab and DHAP. Secondary objective is to prove ability to mobilize stem cells in\n      patients scheduled to high dose therapy.\n\n      In the part II (full target dose) the primary objective is to evaluate the ORR in patients\n      with relapsed diffuse large B cell lymphoma (DLBCL). The secondary objective is to evaluate\n      progression free survival (PFS), overall survival (OS) and Toxicity."
        }, 
        "brief_title": "STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma", 
        "completion_date": {
            "#text": "July 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Diffuse Large B-Cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multicenter, open label, single arm, phase II study. There will be no placebo\n      usage within this trial. In the part I, dose escalation part, of this trial 6 patients will\n      be included in each dose level. There will be 4 cohorts, administering up to a maximum of 4\n      cycles 25 mg, 50 mg, 75mg or 100mg Temsirolimus in combination with Rituximab and DHAP.\n\n      Treatment regimen part I:\n\n      Part I - Cohort A, B, C, D, X Temsirolimus 25 (A), 50 (B), 75 (C),100 (D) or 15 (X) mg, Day\n      1, 8, Rituximab (375 mg/m\u00b2 day 2) Dexamethasone 40mg day 3-6 Cisplatine 100 mg/m\u00b2 day 3\n      Cytarabine 2x2 g/m\u00b2 day 4\n\n      ...repeat day 22, up to a maximum of 4 cycles In part I, after inclusion of 6 patients, each\n      patient has to receive at least 1 complete cycle w/o dose limiting toxicity until the\n      enrollment into the next cohort can be initiated.\n\n      In the part II of the trial 40 patients will be included to receive the full target dose,\n      established within the part I of the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with histologically proven diagnosis of diffuse large cell B-cell lymphoma\n             (DLBCL) according to the World Health Organization classification.\n\n          -  Documented relapse or progression following at least one treatment but a maximum of 2\n             prior treatments. Prior treatment must have included at least 3 cycles of\n             anthracycline containing chemotherapy (e.g. CHOP-like)\n\n          -  Any of the following: at least 1 measurable tumor mass (>1.5 cm x >1.0 cm),\n             involvement of any organ or bone marrow infiltration\n\n          -  Subjects 18 years or older\n\n          -  Subjects (or their legally acceptable representatives) must have signed an informed\n             consent document indicating that they understand the purpose of and procedures\n             required for the study and are willing to participate in the study.\n\n          -  Adequate bone marrow reserve: Platelets of at least 75000/\u00b5l, absolute neutrophil\n             count at least 1500/\u00b5l\n\n          -  Alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN); Aspartate\n             aminotransferase (AST) < 2.5 x ULN, Total bilirubin < 1.5 x ULN\n\n          -  Calculated creatinine clearance (MDRD) > 70 mL/min\n\n          -  Eastern Cooperative Oncology Group [ECOG] performance Status < 3\n\n          -  Female subject must be postmenopausal (for at least 6 months), surgically sterile,\n             abstinent, or, if sexually active, be practicing an effective method of birth control\n             (e.g., prescription oral contraceptives, contraceptive injections, intrauterine\n             device, double-barrier method, contraceptive patch, male partner sterilization)\n             before entry and throughout the study; and have a negative serum \u00df-hCG pregnancy test\n             at screening\n\n        Exclusion Criteria:\n\n          -  Active central nervous System lymphoma. Brain MRI is required only if clinically\n             indicated\n\n          -  Pregnancy or breast feeding women\n\n          -  Lymphoma other than DLBCL\n\n          -  Severe concomitant disease (e.g. uncontrolled arterial hypertension, heart failure\n             (NYHA III-IV), uncontrolled diabetes mellitus, pulmonary fibrosis, uncontrolled\n             hyperlipoproteinemia)\n\n          -  Active uncontrolled infections including HIV-positivity, active Hep B or C\n\n          -  Mental status precluding patient's compliance\n\n          -  Prior treatment with Temsirolimus\n\n          -  Known CD20 negativity\n\n          -  Patients refractory to DHAP in a prior treatment line\n\n          -  Prior autologous or allogeneic stem cell or bone marrow transplantation\n\n          -  Peripheral neuropathy or neuropathic pain of Grade 2 or worse\n\n          -  Diagnosed or treated for a malignancy other than NHL except: adequately treated\n             non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, DCIS of\n             the breast, or other solid tumors curatively treated with no evidence of disease for\n             >5 years\n\n          -  Concurrent treatment with another investigational agent during the conduct of the\n             trial.\n\n          -  Concurrent participation in non-treatment studies is not excluded\n\n          -  Known intolerance to Sirolimus or derivates, Cytarabine, Cisplatine or Rituximab."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "88", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01653067", 
            "org_study_id": "STORM-2011", 
            "secondary_id": "2011-001491-20"
        }, 
        "intervention": {
            "arm_group_label": "Rituximab, Temsirolimus, DHAP, intravenous", 
            "description": "Maximum tolerated dose of Temsirolimus Rituximab (375 mg/m\u00b2) Dexamethasone (120 mg) Cisplatin (100mg/m\u00b2) Cytarabine (2x2g/m\u00b2))", 
            "intervention_name": "Rituximab, Temsirolimus, DHAP, intravenous", 
            "intervention_type": "Drug", 
            "other_name": [
                "Temsirolimus-R-DHAP", 
                "Torisel", 
                "MabThera", 
                "Fortecortin", 
                "ARA-C", 
                "ARA-cell", 
                "Depocyte", 
                "R-DHAP", 
                "Rituximab-DHAP", 
                "Temsirolimus,Rituximab,Dexamethasone,Cisplatine,Cytarabine", 
                "Temsirolimus-Rituximab-DHAP"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Sirolimus", 
                "Everolimus", 
                "Rituximab", 
                "Dexamethasone", 
                "Dexamethasone acetate", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Non Hodgkin\u00b4s Lymphoma", 
            "Diffuse Large B-Cell Lymphoma", 
            "Aggressive Lymphoma", 
            "Aggressive Non Hodgkin\u00b4s Lymphoma", 
            "NHL", 
            "aNHL", 
            "Temsirolimus", 
            "Torisel", 
            "Relapsed Non Hodgkin\u00b4s Lymphoma", 
            "Relapsed Diffuse Large B-Cell Lymphoma", 
            "aggressive NHL", 
            "B-NHL", 
            "aggressive B-NHL"
        ], 
        "lastchanged_date": "August 19, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Gerald Illerhaus, MD", 
                    "phone": "0049-761-27037850"
                }, 
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany", 
                        "state": "Baden-W\u00fcrttemberg", 
                        "zip": "79106"
                    }, 
                    "name": "University Hospital Freiburg"
                }, 
                "investigator": {
                    "last_name": "Gerald Illerhaus, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mathias.witzens-harig@med.uni-heidelberg.de", 
                    "last_name": "Mathias Witzens-Harig, MD", 
                    "phone": "+49 6221 568008"
                }, 
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "state": "Baden-W\u00fcrttemberg", 
                        "zip": "69120"
                    }, 
                    "name": "University of Heidelberg Hospital"
                }, 
                "investigator": {
                    "last_name": "Mathias Witzens-Harig, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Andreas Viardot, MD", 
                    "phone": "0049-731-50045539"
                }, 
                "facility": {
                    "address": {
                        "city": "Ulm", 
                        "country": "Germany", 
                        "state": "Baden-W\u00fcrttemberg", 
                        "zip": "89081"
                    }, 
                    "name": "University Hospital Ulm"
                }, 
                "investigator": {
                    "last_name": "Andreas Viardot, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Stefan W. Krause, Prof.", 
                    "phone": "0049-9131-8535957"
                }, 
                "facility": {
                    "address": {
                        "city": "Erlangen", 
                        "country": "Germany", 
                        "state": "Bayern", 
                        "zip": "91054"
                    }, 
                    "name": "University Hospital Erlangen"
                }, 
                "investigator": {
                    "last_name": "Stefan W. Krause, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ulrich Keller, MD", 
                    "phone": "0049-89-41407435"
                }, 
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany", 
                        "state": "Bayern", 
                        "zip": "81675"
                    }, 
                    "name": "Technische Universit\u00e4t M\u00fcnchen"
                }, 
                "investigator": {
                    "last_name": "Ulrich Keller, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Martin Dreyling, Prof.", 
                    "phone": "0049-89-70952202"
                }, 
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany", 
                        "state": "Bayern", 
                        "zip": "81377"
                    }, 
                    "name": "Ludwig-Maximilians-University of Munich"
                }, 
                "investigator": {
                    "last_name": "Martin Dreyling, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Johannes Atta, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "state": "Hessen", 
                        "zip": "60590"
                    }, 
                    "name": "Johann Wolfgang Goethe University Hospitals, Frankfurt"
                }, 
                "investigator": {
                    "last_name": "Johannes Atta, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Georg He\u00df, MD", 
                    "phone": "0049-6131-175040"
                }, 
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany", 
                        "state": "Rheinland-Pfalz", 
                        "zip": "55101"
                    }, 
                    "name": "Johannes Guttenberg University Mainz"
                }, 
                "investigator": {
                    "last_name": "Georg He\u00df, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Agnieszka Korfel, MD", 
                    "phone": "0049-30-84452337"
                }, 
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "12200"
                    }, 
                    "name": "Charit\u00e9 University Berlin"
                }, 
                "investigator": {
                    "last_name": "Agnieszka Korfel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Trial to Evaluate the Safety, Feasibility and Efficacy of a Salvage Therapy Consisting of Temsirolimus Added to the Standard Therapy R-DHAP for the Treatment of Patients With Relapsed or Refractory DLBCL - the STORM Trial", 
        "overall_contact": {
            "email": "mathias.witzens-harig@med.uni-heidelberg.de", 
            "last_name": "Mathias Witzens-Harig, MD", 
            "phone": "0049 6221 56 8199"
        }, 
        "overall_official": {
            "affiliation": "University Hospital of Heidelberg, Department 5 Hematology, Oncology, Rheumatology, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany", 
            "last_name": "Mathias Witzens-Harig, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Ethics Commission", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "In the part I  (dose escalation of Temsirolimus) the primary objective is to establish a maximum tolerated dose of Temsirolimus in combination with Rituximab and DHAP.", 
            "measure": "Safety, Tolerability and Efficacy of a combination therapy of Temsirolimus added to the standard therapy, Rituximab and DHAP (Cytarabine, Cisplatine, Dexamethasone)", 
            "safety_issue": "Yes", 
            "time_frame": "09-2012 to 06-2018 (up to six years)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01653067"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital Heidelberg", 
            "investigator_full_name": "Mathias Witzens-Harig", 
            "investigator_title": "PD Dr. med. Mathias Witzens-Harig", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "In the part I  (dose escalation of Temsirolimus) secondary objective is to prove ability to mobilize stem cells in patients scheduled to high dose therapy.", 
                "measure": "Safety, Tolerability and Efficacy of a combination therapy of Temsirolimus added to the standard therapy, Rituximab and DHAP (Cytarabine, Cisplatine, Dexamethasone)", 
                "safety_issue": "Yes", 
                "time_frame": "09-2012 to 06-2018 (up to six years)"
            }, 
            {
                "description": "In the part II (full target dose) the secondary objective is to evaluate Progression Free Survival", 
                "measure": "Safety, Tolerability and Efficacy of a combination therapy of Temsirolimus added to the standard therapy, Rituximab and DHAP (Cytarabine, Cisplatine, Dexamethasone)", 
                "safety_issue": "Yes", 
                "time_frame": "09-2012 to 06-2018 (up to six years)"
            }, 
            {
                "description": "In the part II (full target dose) the secondary objective is to evaluate Overall Survival", 
                "measure": "Safety, Tolerability and Efficacy of a combination therapy of Temsirolimus added to the standard therapy, Rituximab and DHAP (Cytarabine, Cisplatine, Dexamethasone)", 
                "safety_issue": "Yes", 
                "time_frame": "09-2012 to 06-2018 (up to six years)"
            }, 
            {
                "description": "In the part II (full target dose) the secondary objective is to evaluate Toxicity", 
                "measure": "Safety, Tolerability and Efficacy of a combination therapy of Temsirolimus added to the standard therapy, Rituximab and DHAP (Cytarabine, Cisplatine, Dexamethasone)", 
                "safety_issue": "Yes", 
                "time_frame": "09-2012 to 06-2018 (up to six years)"
            }
        ], 
        "source": "University Hospital Heidelberg", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Johannes Gutenberg University Mainz", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Technische Universit\u00e4t M\u00fcnchen", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Ludwig-Maximilians - University of Munich", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University Hospital Ulm", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University Hospital Erlangen", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Charite University, Berlin, Germany", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University Hospital Freiburg", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Johann Wolfgang Goethe University Hospitals", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Mathias Witzens-Harig", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}